Powerae.com
Why Dr. Brad Stanfield Chooses Low-Dose Tirzepatide Over Retatrutide: A New Perspective on GLP-1 Medications and Long-Term Health
buy selank peptide for sale
As GLP-1 medications continue to transform the treatment of obesity and type 2 diabetes, growing research is raising a broader question: Could these drugs offer health benefits beyond weight loss?
In a recent discussion, Australian general practitioner and health educator Dr. Brad Stanfield explains why he personally chooses low-dose tirzepatide rather than newer experimental medications such as retatrutide. His perspective highlights the evolving science of metabolic health, cardiovascular protection, joint health, and the importance of balancing potential benefits against individual risks.
Importantly, Stanfield’s decision reflects his personal approach and should not be interpreted as a general recommendation for people who are not overweight or do not have diabetes.
## Beyond Weight Loss: The Expanding Science of GLP-1 Medications
GLP-1 receptor agonists were initially developed to help manage blood glucose levels and later became widely recognized for their ability to support weight loss. Tuttavia, researchers are increasingly investigating whether these medications may influence other biological systems independently of changes in body weight.
Large clinical trials have provided important evidence. The SELECT trial found that semaglutide reduced the risk of major cardiovascular events in people with overweight or obesity and established cardiovascular disease who did not have diabetes. The FLOW trial also demonstrated kidney-related benefits in people with type 2 diabetes and chronic kidney disease.
These findings suggest that GLP-1 medications may have effects extending beyond appetite regulation and weight reduction. Researchers are investigating their potential influence on inflammation, cardiovascular function, kidney health, and other metabolic pathways.
Tuttavia, results from one medication or patient population cannot automatically be applied to every GLP-1 drug or healthy individual. The benefits depend on the specific medication, clinical condition, and available evidence.
## Could GLP-1 Medications Help Protect Joint Health?
One particularly interesting research direction involves osteoarthritis and cartilage health.
Traditionally, weight loss has been considered beneficial for knee osteoarthritis because reducing body weight decreases the mechanical pressure placed on the joints. But emerging research suggests that GLP-1 signaling may also have biological effects on cartilage.
Research discussed by Stanfield includes work from scientists in China investigating semaglutide and osteoarthritis. The findings suggest that GLP-1 receptor activation may influence cartilage-cell metabolism and help protect joint tissue. Experimental research has explored whether these effects could occur beyond the mechanical benefits associated with weight reduction.
This is an exciting area of investigation, but it is important to distinguish early scientific findings from established clinical treatment. Animal experiments and emerging human research do not yet establish GLP-1 medications as approved treatments for cartilage regeneration or osteoarthritis.
Nevertheless, the possibility that metabolic medications could influence joint health through mechanisms beyond weight loss represents an important direction for future research.
## Why Tirzepatide Instead of Semaglutide?
A central part of Stanfield’s explanation concerns the difference between semaglutide and tirzepatide.
Semaglutide primarily activates the GLP-1 receptor. Tirzepatide, by contrast, activates both the GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. This dual-action mechanism can influence appetite, glucose regulation, and body weight.
For Stanfield, this combination makes tirzepatide an appealing option to consider.
Cardiovascular research has also added important information. The SURPASS-CVOT trial, published in the *New England Journal of Medicine* in December 2025, compared tirzepatide with dulaglutide in people with type 2 diabetes and established atherosclerotic cardiovascular disease.
The study included more than 13,000 participants. Tirzepatide met the trial’s criteria for non-inferiority compared with dulaglutide for the primary cardiovascular outcome, which included cardiovascular death, heart attack, and stroke. Tuttavia, it did not demonstrate statistically significant superiority for that primary outcome.
A subsequent analysis explored a broader combination of cardiovascular and kidney outcomes, reporting a lower incidence in the tirzepatide group. These findings provide additional research interest, although the analysis should not be confused with proof that tirzepatide is superior for every cardiovascular or kidney outcome.
For people considering these medications, the distinction between trial results, secondary analyses, and personal treatment decisions remains essential.
Retatrutide has attracted considerable attention because it targets three hormone receptors: GLP-1, GIP, and glucagon.
The addition of glucagon receptor activity makes retatrutide different from currently established dual-action treatments. Researchers are investigating whether this mechanism can increase energy expenditure while also reducing appetite and body weight.
Stanfield questions whether this additional metabolic activity is necessarily desirable for someone who is already relatively lean and wants to maintain muscle mass.
For individuals whose primary goal is substantial weight reduction, increased energy expenditure may be an attractive research feature. But for someone who does not need to lose much weight, further reductions in body mass could be undesirable.
Retatrutide has also been associated with increases in resting heart rate in clinical studies. This is an important consideration when evaluating a medication that affects several metabolic pathways.
Tuttavia, retatrutide remains an investigational medication, and its long-term safety profile and cardiovascular effects require further clinical research. It is too early to conclude that it is inherently less safe than tirzepatide or unsuitable for particular groups based solely on its mechanism.
Stanfield’s preference is therefore best understood as a personal judgment about his own health goals, rather than a definitive comparison of the two drugs.
## Stanfield’s Personal Experience With Low-Dose Tirzepatide
One of the most discussed aspects of the video is Stanfield’s description of his personal dosing approach.
He reports using 1.25 mg of tirzepatide once weekly. This is a personal regimen and is not an established standard maintenance dose or a generally recommended preventive treatment.
According to his account, one noticeable effect has been a reduction in what is commonly called “food noise” — persistent thoughts about food, cravings, or the urge to eat.
He says this has made it easier for him to maintain healthy eating habits. He also reports that his blood pressure medication requirements have decreased by approximately half.
These observations are personal experiences, not evidence that low-dose tirzepatide can reliably reduce blood pressure medication requirements in other people. Any adjustment to blood pressure treatment should be based on clinical measurements and made with a healthcare professional.
Stanfield also describes experiencing mild nausea and fatigue when he first started treatment. These symptoms gradually improved over time.
## Nutrition and Muscle Preservation Matter
Another important issue is nutritional intake.
GLP-1 medications can reduce appetite substantially, which may lead some users to consume fewer calories and a narrower range of foods. If dietary intake falls too far, people may struggle to obtain adequate protein, vitamins, minerals, and other essential nutrients.
For this reason, Stanfield says he uses a third-party-tested multivitamin and mineral supplement as part of his personal nutritional approach.
His comments highlight a broader principle: reducing appetite does not automatically mean that nutritional needs are being met.
People using appetite-suppressing medications should pay attention to protein intake, dietary variety, hydration, and resistance exercise. These habits may be particularly important for maintaining muscle mass during weight loss.
A supplement can help address certain nutritional gaps, but it cannot replace a balanced diet or guarantee that deficiencies will not occur. Supplement choices should be based on individual needs rather than assumed to be necessary for everyone.
## The Bigger Picture: Personalization Over Popularity
The discussion reflects a changing conversation around GLP-1 medications. Their potential effects may extend beyond weight management, but the evidence is still developing across several areas of long-term health.
Tirzepatide and retatrutide have different mechanisms, and their potential benefits and risks cannot be judged simply by counting the number of receptors they activate. More clinical evidence is needed to understand how these medications compare across different populations and long-term health outcomes.
Perhaps the most important takeaway from Stanfield’s discussion is that medication choices should be guided by individual health goals, medical history, and a careful assessment of risks and benefits — not social media trends or the assumption that a more powerful drug is always better.
**Medical Disclaimer:** This article is for informational and educational purposes only. Tirzepatide is a prescription medication with approved uses that vary by country and product. Retatrutide remains investigational. Low-dose or off-label use should not be considered a general health or anti-aging strategy. Do not start, stop, or change medication without consulting a qualified healthcare professional.